Introducing Hizentra

20% Subcutaneous Immunoglobulin (SCIg) Therapy for PIDD

Hizentra is an immunoglobulin (Ig) replacement therapy that you infuse yourself, using a small needle and infusion pump. It is approved by the US Food and Drug Administration (FDA) for people with primary immunodeficiency disease (PIDD, sometimes known as just PI). Because Hizentra is ready to use at room temperature, you can infuse whether you’re at home or on the go.

Stable, Convenient Protection Against Infection

Hizentra provides you with stable, steady-state Ig levels, whether infused weekly or biweekly (every 2 weeks). In addition, Hizentra:

  • Delivers an Ig dose in half the volume of 10% solutions because it is a 20% concentration*
  • Can be stored at room temperature for up to 30 months (up to 77°F [25°C])
  • Maintains a consistent level of protection against infection5
  • Provides proven protection and safety
  • Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. Because Hizentra contains the amino acid proline as stabilizer, patients with hyperprolinemia (too much proline in the blood) should not take Hizentra.

Weekly or Biweekly Self-Administration to Fit Your Lifestyle

  • Work with your healthcare professional to choose whether weekly or biweekly infusion is right for you
  • You can do certain activities while you infuse
  • You can infuse at a time that’s most convenient for you
  • You can take it with you and infuse when and where it is most convenient because Hizentra does not need refrigeration.
  • Infuse Hizentra under your skin only; do not inject into a blood vessel. Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

* Based on an equivalent dose in grams.

Hear Carla Duff, ARNP Discuss the Benefits of SCIg Therapy

Patient/Caregiver About Hizentra Overview of Hizentra
Expand

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Collapse
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2014 CSL Behring. The product information presented on this site is intended for US residents only. HIZ14-01-0001 3/2014